m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00503)
Name
EFT508
Synonyms
Tomivosertib; eFT508; 1849590-01-7; EFT-508; UNII-U2H19X4WBV; U2H19X4WBV; Tomivosertib [INN]; Tomivosertib [USAN]; SCHEMBL17362622; GTPL10167; eFT-508 (eFT508); EFT 508; MolPort-044-560-418; BCP18993; EX-A2494; ZINC575623807; AKOS030627405; CS-5841; compound 23 [PMID: 29526098]; HY-100022; S8275; 6'-((6-aminopyrimidin-4-yl)amino)-8'-methyl-1'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'(2'H)-dione; 6-[(6-aminopyrimidin-4-yl)amino]-8-methylspiro[2H-imidazo[1,5-a]pyridine-3,1'-cyclohexane]-1,5-dione
    Click to Show/Hide
Status
Phase 2
Structure
Formula
C17H20N6O2
InChI
1S/C17H20N6O2/c1-10-7-11(21-13-8-12(18)19-9-20-13)16(25)23-14(10)15(24)22-17(23)5-3-2-4-6-17/h7-9H,2-6H2,1H3,(H,22,24)(H3,18,19,20,21)
InChIKey
HKTBYUWLRDZAJK-UHFFFAOYSA-N
PubChem CID
118598754
TTD Drug ID
D07XOV
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
MAP kinase signal-integrating kinase 2 (MKNK2)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary MAP kinase signal-integrating kinase 2 (MKNK2) is a therapeutic target for EFT508. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of EFT508 through regulating the expression of MAP kinase signal-integrating kinase 2 (MKNK2). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary MAP kinase signal-integrating kinase 2 (MKNK2) is a therapeutic target for EFT508. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of EFT508 through regulating the expression of MAP kinase signal-integrating kinase 2 (MKNK2). [1], [2]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary MAP kinase signal-integrating kinase 2 (MKNK2) is a therapeutic target for EFT508. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of EFT508 through regulating the expression of MAP kinase signal-integrating kinase 2 (MKNK2). [1], [2]
References
Ref 1 Dynamic m(6)A mRNA Methylation Reveals the Role of METTL3/14-m(6)A-MNK2-ERK Signaling Axis in Skeletal Muscle Differentiation and Regeneration. Front Cell Dev Biol. 2021 Oct 1;9:744171. doi: 10.3389/fcell.2021.744171. eCollection 2021.
Ref 2 Stimulator of IFN genes mediates neuroinflammatory injury by suppressing AMPK signal in experimental subarachnoid hemorrhage. J Neuroinflammation. 2020 May 25;17(1):165. doi: 10.1186/s12974-020-01830-4.